Dacomitinib Improves Chemosensitivity of Cisplatin-resistant Human Ovarian Cancer Cells

Overview

Journal Oncol Lett

Specialty Oncology

Date 2021 Jun 11

PMID 34113397

Citations 3

Authors

Lei Xu

Ying Xu

Jianbing Zheng

Yun Zhao

Hongcai Wang

Yushu Qi

Affiliations

Soon will be listed here.

Abstract

Drug resistance hinders effectiveness of human ovarian cancer (OC) therapies, such as cisplatin or paclitaxel therapy. Although dacomitinib, a novel anticancer agent is used against multiple types of cancers, such as non-small cell lung cancer, head and neck cancer, few studies report its effectiveness in drug-resistant human OC cells. In the present study, would healing, microplate spectrophotometer analysis, flow cytometry analysis, western blotting and Gene Expression Omnibus (GEO) analysis were used to detect the synergistic effect of dacomitinib and cisplatin in human OC SKOV-3 or OV-4 cells. Co-administration of dacomitinib and cisplatin significantly reduced viability and promoted cell apoptosis of drug resistant OC cells. In addition, dacomitinib increased Cadherin 1 (CDH1) levels and decreased P-glycoprotein (P-GP) levels in cisplatin-resistant OC cells. In addition, GEO analysis demonstrated that dacomitinib inhibited the epidermal growth factor receptor (EGFR) signaling pathway. In summary, dacomitinib improves chemosensitivity of cisplatin in human OC by regulating CDH1 and P-GP protein levels and inhibiting the EGFR signaling pathway.

Citing Articles

Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells.

Lim Y, Kim H, Bae S, So K, Kim T, Lee J Molecules. 2024; 29(1).

PMID: 38202856 PMC: 10780346. DOI: 10.3390/molecules29010274.

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.

Li Y, Mao T, Wang J, Zheng H, Hu Z, Cao P Cell Commun Signal. 2023; 21(1):71.

PMID: 37041601 PMC: 10088170. DOI: 10.1186/s12964-023-01082-8.

Drug-induced liver injury associated with dacomitinib: A case report.

Wang X, Huang A, Lu Y, Gao S, Hu W, Cheng H Front Oncol. 2022; 12:979462.

PMID: 36185261 PMC: 9515502. DOI: 10.3389/fonc.2022.979462.

References

Xu L, Cai J, Yang Q, Ding H, Wu L, Li T . Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies. J Cancer Res Clin Oncol. 2013; 139(8):1257-77. DOI: 10.1007/s00432-013-1435-z. View

Pang J, Jiang P, Wang Y, Jiang L, Qian H, Tao Y . Cross-linked hyaluronan gel inhibits the growth and metastasis of ovarian carcinoma. J Ovarian Res. 2018; 11(1):22. PMC: 5840805. DOI: 10.1186/s13048-018-0394-z. View

Liao B, Lin C, Yang J . Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015; 27(2):94-101. DOI: 10.1097/CCO.0000000000000164. View

Gordon A, Finkler N, Edwards R, Garcia A, Crozier M, Irwin D . Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer. 2005; 15(5):785-92. DOI: 10.1111/j.1525-1438.2005.00137.x. View

Passaro A, Mok T, Peters S, Popat S, Ahn M, de Marinis F . Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. J Thorac Oncol. 2020; 16(5):764-773. DOI: 10.1016/j.jtho.2020.12.002. View

Hurvitz S, Caswell-Jin J, McNamara K, Zoeller J, Bean G, Dichmann R . Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nat Commun. 2020; 11(1):5824. PMC: 7673127. DOI: 10.1038/s41467-020-19494-2. View

Engelman J, Zejnullahu K, Gale C, Lifshits E, Gonzales A, Shimamura T . PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007; 67(24):11924-32. DOI: 10.1158/0008-5472.CAN-07-1885. View

Angioli R, Palaia I, Zullo M, Muzii L, Manci N, Calcagno M . Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol. 2005; 100(3):455-61. DOI: 10.1016/j.ygyno.2005.09.060. View

Camblin A, Tan G, Curley M, Yannatos I, Iadevaia S, Rimkunas V . Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Sci Rep. 2019; 9(1):16832. PMC: 6856132. DOI: 10.1038/s41598-019-53322-y. View

10.

Gottesman M, Pastan I . Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993; 62:385-427. DOI: 10.1146/annurev.bi.62.070193.002125. View

11.

Poursheikhani A, Yousefi H, Tavakoli-Bazzaz J, Seyed H G . EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells. Iran Biomed J. 2020; 24(6):370-8. PMC: 7601546. DOI: 10.29252/ibj.24.6.365. View

12.

Miao Y, Liu G, Liu L . Histone methyltransferase SUV39H2 regulates LSD1-dependent CDH1 expression and promotes epithelial mesenchymal transition of osteosarcoma. Cancer Cell Int. 2021; 21(1):2. PMC: 7784292. DOI: 10.1186/s12935-020-01636-7. View

13.

Gonzales A, Hook K, Althaus I, Ellis P, Trachet E, Delaney A . Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2008; 7(7):1880-9. DOI: 10.1158/1535-7163.MCT-07-2232. View

14.

Perrotta C, Cervia D, Di Renzo I, Moscheni C, Bassi M, Campana L . Nitric Oxide Generated by Tumor-Associated Macrophages Is Responsible for Cancer Resistance to Cisplatin and Correlated With Syntaxin 4 and Acid Sphingomyelinase Inhibition. Front Immunol. 2018; 9:1186. PMC: 5987706. DOI: 10.3389/fimmu.2018.01186. View

15.

Klymenko Y, Kim O, Stack M . Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer. Cancers (Basel). 2017; 9(8). PMC: 5575607. DOI: 10.3390/cancers9080104. View

16.

Chen Q, Liu X, Luo Z, Wang S, Lin J, Xie Z . Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression. J Cell Physiol. 2018; 234(5):6611-6623. DOI: 10.1002/jcp.27402. View

17.

Pradeep S, Kim S, Wu S, Nishimura M, Chaluvally-Raghavan P, Miyake T . Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014; 26(1):77-91. PMC: 4100212. DOI: 10.1016/j.ccr.2014.05.002. View

18.

Sun H, Wu Y . Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application. Future Oncol. 2019; 15(23):2769-2777. DOI: 10.2217/fon-2018-0535. View

19.

Hyokai S, Tanaka H, Aihara N, Kamiie J . Expression of P-glycoprotein and breast cancer resistance protein in three cases of canine lymphoma showing drug resistance. J Vet Med Sci. 2021; 83(3):473-477. PMC: 8025433. DOI: 10.1292/jvms.20-0718. View

20.

Toolabi M, Moghimi S, Oghabi Bakhshaiesh T, Salarinejad S, Aghcheli A, Hasanvand Z . 6-Cinnamoyl-4-arylaminothienopyrimidines as highly potent cytotoxic agents: Design, synthesis and structure-activity relationship studies. Eur J Med Chem. 2019; 185:111786. DOI: 10.1016/j.ejmech.2019.111786. View